Is government action actually coming for the price of pharmaceuticals in the U.S.? It’s been a campaign promise going back to 2015, from both sides of the political aisle, but nothing substantial has changed.
Janssen Biotech has entered into a definitive agreement to acquire a privately-held biopharmaceutical company focused on the red-hot field of cancer immunology.
Financial terms of the deal for BeneVir BioPharm are being kept confidential.
Students at UMB are looking to form new startups that will bring change to a range of different areas in healthcare and beyond, from the pockets where nurses keep supplies to the ways that drugs are delivered.
When Twist Bioscience Corp. started in Mission Bay five years ago with the idea of making synthetic genes for researchers, it consisted of Emily Leproust and her two co-founders. Today, the 240-employee company is priming to move to nearly 61,000 square feet in South San Francisco.
A pair of Baltimore-based tech leaders are joining the board of directors for TEDCO.
With the appointment by Gov. Larry Hogan, each will serve a four-year term on the board that oversees the state’s quasi-public agency backing early-stage tech companies.
“Commercializing Technologies for Societal Impact”
The governments of the United States of America (through the Department of State) and India (through the Department of Science & Technology) have established the United States – India Science & Technology Endowment Fund (USISTEF) for the promotion of joint activities that would lead to innovation and technopreneurship through the application of science and technology. The Endowment Fund activities are implemented and administered through the bi-national Indo-U.S. Science and Technology Forum (IUSSTF).
HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”).
When: Thursday, May 17, 20184:00 – 7:00 PM EST
Where: University of Maryland BioPark, 801 West Baltimore Street, Baltimore, MD 21201
Join the fourth in the TEDCO funded Anchor Ventures events series for an important discussion about Talent. Our expert panel will discuss how to draw the right candidates to your company, the role personnel plays in the investment process, opportunities for enhancing your existing team, and the regional supply of entrepreneurial talent.
The National Institute of Standards and Technology is looking for the public’s help in refreshing how it uses research and development funds to help bring new products to market.
The digital health rocket seems to have gotten supercharged lately, at least when it comes to fundraising. Depending on who you ask, either $1.62 billion (Rock Health’s count) or $2.5 billion (Mercom) or $2.8 billion (Startup Health’s count) was plowed into digital health companies in just the first three months of 2018. By any measure Q1 2018 was the most significant quarter yet for digital health funding. This headline has been everywhere. Digital health: to infinity and beyond! But what is the significance of this? Should investors and customers of these companies be excited or worried? It’s a little hard to tell.